Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Biologic therapies for spondyloarthritis: what is new?

Baraliakos X, Braun J.

Curr Rheumatol Rep. 2012 Oct;14(5):422-7. doi: 10.1007/s11926-012-0282-2. Review.

PMID:
22855297
2.

Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.

Callhoff J, Sieper J, Weiß A, Zink A, Listing J.

Ann Rheum Dis. 2015 Jun;74(6):1241-8. doi: 10.1136/annrheumdis-2014-205322. Epub 2014 Apr 9. Review.

PMID:
24718959
3.

TNF-alpha inhibitors for ankylosing spondylitis.

Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2015 Apr 18;(4):CD005468. doi: 10.1002/14651858.CD005468.pub2. Review.

PMID:
25887212
4.

Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.

Machado MA, Barbosa MM, Almeida AM, de Araújo VE, Kakehasi AM, Andrade EI, Cherchiglia ML, Acurcio Fde A.

Rheumatol Int. 2013 Sep;33(9):2199-213. doi: 10.1007/s00296-013-2772-6. Epub 2013 May 18. Review.

PMID:
23686218
5.

Biologic therapies in the spondyloarthritis: new opportunities, new challenges.

Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J.

Curr Opin Rheumatol. 2003 Jul;15(4):394-407. Review.

PMID:
12819466
6.

Update on biologic therapy in the management of axial spondyloarthritis.

Heldmann F, Dybowski F, Saracbasi-Zender E, Fendler C, Braun J.

Curr Rheumatol Rep. 2010 Oct;12(5):325-31. doi: 10.1007/s11926-010-0125-y.

PMID:
20665135
7.

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.

Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M.

PLoS One. 2012;7(1):e30275. doi: 10.1371/journal.pone.0030275. Epub 2012 Jan 17. Review.

8.

Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.

Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E, Moe-Byrne T, Fox D, Marzo-Ortega H, Kay L, Woolacott N, Palmer S.

Health Technol Assess. 2016 Feb;20(9):1-334, v-vi. doi: 10.3310/hta20090. Review.

9.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

10.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

11.

TNF-α antagonists beyond approved indications: stories of success and prospects for the future.

Karampetsou MP, Liossis SN, Sfikakis PP.

QJM. 2010 Dec;103(12):917-28. doi: 10.1093/qjmed/hcq152. Epub 2010 Aug 27. Review.

PMID:
20802008
12.

Certolizumab pegol in axial spondyloarthritis.

Song IH, Rudwaleit M.

Expert Rev Clin Immunol. 2013 Dec;9(12):1161-72. doi: 10.1586/1744666X.2013.858859. Review.

PMID:
24215406
13.

[Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].

Amano K.

Nihon Naika Gakkai Zasshi. 2011 Oct 10;100(10):2966-71. Review. Japanese. No abstract available.

PMID:
22175139
15.

[Biological therapies in rheumatology].

Von Frenckell C, Malaise MG.

Rev Med Liege. 2009 May-Jun;64(5-6):293-300. French.

16.

Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.

Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, Iannone F, Lapadula G.

Drug Dev Res. 2014 Nov;75 Suppl 1:S77-80. doi: 10.1002/ddr.21203.

PMID:
25381986
17.

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.

J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11.

PMID:
22563743
18.

Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.

Dhillon S.

Drugs. 2014 Jun;74(9):999-1016. doi: 10.1007/s40265-014-0239-z. Review.

PMID:
24919863
19.

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.

Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN.

Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17.

PMID:
24359625
20.

An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis.

Paccou J, Flipo RM.

Drug Des Devel Ther. 2016 Jul 11;10:2255-62. doi: 10.2147/DDDT.S91441. eCollection 2016. Review.

Supplemental Content

Support Center